MAM
PUMA goes gully centric in new music video
MUMBAI: Sportswear brand PUMA has launched its new music video pioneering the largest movement in street culture in the country. Titled ‘Suede Gully’, this is the first time a global brand has launched a multi-lingual music video in India, giving this channel for consumer engagement a fresh spin.
The video is a large-scale collaboration between a new breed of artists, musicians and dancers, whose work is inspired from the stories ingrained in the streets of India. In another first for a global consumer brand, this music video is coloured in local flavours, features multiple Indian languages and celebrates the culture germinating from Indian streets.
This collaboration gives a single, creative stage for self-expression to these artists, who come from “gullies” across the country. Featuring eight rappers, 36 dancers, seven artists and countless creators, Suede Gully is the largest street collaboration that brings out the true essence of the streets of India in its most musical, colourful and rebellious manner.
Shot in gullies across all regions of India, the video features leading street artists Divine, Mukti Mohan and Shilo Shiv Suleiman. The music video has been directed by Sasha Rainbow and the music has been composed by Sneha Khanwalkar. With lyrics in four different Indian languages, it adds to the local flavor and serves as a medium to popularize Indian street culture. This video is a celebration of street art in the purest form, bringing out the passion, the determination, the resourcefulness and grit of each artist.
PUMA India MD Abhishek Ganguly says, “The Suede Gully is an authentic music video that connects with the audience with its super cool street swagger. Suede Gully is something new and unique, serving as a single platform for self-expression to a number of independent, determined artists who live their passion and hustle to achieve their goals.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
